The first case of an IgAV patient was published by Allez et al. It was a 24-year-old man with Crohn’s disease treated with TNFα inhibitors, who developed skin lesions, joint complaints, and abdominal pain during COVID-19 infection. This evidence concerns the gene TNF and Crohn disease.